1253197-41-9

Upstream product

• 1253197-35-1 (+/-)-cis-7-(benzyloxy)-3-(4-phenylcyclohexyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 81593-56-8 [[2-(3-Methoxy-phenyl)-ethyl]-(toluene-4-sulfonyl)-amino]-acetic acid 
• 81593-57-9 7-methoxy-3-(4-methylphenylsulfonyl)-2,3,4,5-tetrahydro-3-benzazepin-1-one 
• 4894-75-1 1-phenyl-4-cyclohexanone 
• 64880-89-3 N-[(3-methoxyphenyl)ethyl]-4′′-methylbenzenesulfonamide 
• 1253197-27-1 7-hydroxy-3-(4-tosyl)-2,3,4,5-tetrahydro-3-benzazepine-1-one 
• 1253197-29-3 (+/-)-7-benzyloxy-3-(4-tosyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1253197-26-0 (+/-)-7-benzyloxy-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 

Relevant academic research and scientific papers

NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES

The present invention provides novel means and methods for treatment auf immunemediated inflammatory diseases.

Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols

NR2B selective NMDA receptor antagonists with tetrahydro-3-benzazepine-1,7- diol scaffold have been designed by formal cleavage and reconstitution of the piperidine ring of the lead compound ifenprodil (1). The secondary amine 10 represents the central bu